

Hidehito Horinouchi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1959922/hidehito-horinouchi-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

895
citations

15
h-index

28
g-index

68
ext. papers

1,179
ext. citations

4.2
avg. IF

3.92
L-index

#	Paper	IF	Citations
61	Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world.. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022 , 1	4.9	0
60	Performance of Japanese patients in registrational studies.. <i>Japanese Journal of Clinical Oncology</i> , 2022 , 52, 53-64	2.8	
59	Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study.. <i>Lung Cancer</i> , 2021 , 165, 152-163	5.9	1
58	Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.. <i>European Journal of Cancer</i> , 2021 , 162, 1-10	7.5	2
57	A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study). <i>Clinical Lung Cancer</i> , 2021 ,	4.9	1
56	Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9044-9044	2.2	2
55	Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study. <i>Cancer Science</i> , 2021 , 112, 3255-3265	6.9	5
54	Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 245-251	4.9	12
53	Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 106-113	2.8	3
52	Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥50%) NSCLC. <i>Clinical Lung Cancer</i> , 2021 , 22, 127-133.e3	4.9	3
51	Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma. <i>Clinical Lung Cancer</i> , 2021 , 22, 282-291.e6	4.9	4
50	Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	0
49	Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2078-2090	8.9	6
48	First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. <i>Cancer Science</i> , 2021 , 112, 5000-5010	6.9	1
47	Salvage surgery after chemotherapy and/or radiotherapy including SBRT and proton therapy: A consecutive analysis of 38 patients. <i>Lung Cancer</i> , 2020 , 145, 105-110	5.9	4
46	Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance. <i>Npj Precision Oncology</i> , 2020 , 4, 15	9.8	11
45	Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure. <i>Thoracic Cancer</i> , 2020 , 11, 1038-1044	3.2	

44	Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer. <i>Cancer Science</i> , 2020 , 111, 1933-1942	6.9	9
43	Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020 , 140, 28-36	7.5	6
42	First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. <i>Cancer Science</i> , 2020 , 111, 4480-4489	6.9	13
41	Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study. <i>Cancer Medicine</i> , 2020 , 9, 6597-6608	4.8	13
40	Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. <i>Thoracic Cancer</i> , 2020 , 11, 3585-3595	3.2	9
39	Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma. <i>Cancer Medicine</i> , 2020 , 9, 7418-7427	4.8	3
38	History of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group. <i>Japanese Journal of Clinical Oncology</i> , 2020 , 50, 502-511	2.8	1
37	Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer. <i>Cancer Science</i> , 2019 , 110, 3573-3583	6.9	2
36	Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. <i>Lung Cancer</i> , 2019 , 137, 64-70	5.9	5
35	Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. <i>European Journal of Cancer</i> , 2019 , 113, 78-86	7.5	45
34	Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 1141-1148	3.2	5
33	Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies. <i>Cancer Medicine</i> , 2019 , 8, 5183-5193	4.8	9
32	Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019 , 20, e317-e328	4.9	16
31	Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial. <i>ESMO Open</i> , 2018 , 3, e000288	6	5
30	An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 685-694	3.5	1
29	Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2018 , 124, 179-188	5.9	35
28	Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations. <i>ESMO Open</i> , 2018 , 3, e000399	6	4
27	Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies. <i>ESMO Open</i> , 2018 , 3, e000342	6	5

26	Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017 , 18, 234-240.e2	4.9	5
25	Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non-small-cell Lung Cancer Developing After Surgery. <i>Clinical Lung Cancer</i> , 2017 , 18, e441-e448	4.9	11
24	History and Future of Multimodality Treatment for N2 NSCLC. <i>Japanese Journal of Lung Cancer</i> , 2017 , 57, 167-174	0.1	
23	The prospect of patritumab for treating non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1549-1555	5.4	3
22	Role of multimodality therapy in cIIIA-N2 non-small cell lung cancer: perspective. <i>Japanese Journal of Clinical Oncology</i> , 2016 , 46, 1174-1178	2.8	3
21	Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy. <i>Lung Cancer</i> , 2016 , 99, 4-10	5.9	61
20	Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 94, 155-162	4	6
19	Medical treatment involving investigational drugs and genetic profile of thymic carcinoma. <i>Lung Cancer</i> , 2016 , 93, 77-81	5.9	10
18	Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016 , 5, 78-81	4.4	5
17	Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2015 , 33, 881-9	4.3	40
16	Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. <i>Lung Cancer</i> , 2015 , 88, 154-9	5.9	113
15	Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. <i>Lung Cancer</i> , 2015 , 89, 287-93	5.9	25
14	Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015 , 16, 385-90	4.9	94
13	Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 91, 140-8	4	38
12	Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma. <i>BMC Research Notes</i> , 2015 , 8, 800	2.3	32
11	Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2015 , 88, 275-81	5.9	32
10	Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer. <i>Cancer Science</i> , 2015 , 106, 1402-7	6.9	9
9	A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC). <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 37-43	3.5	11

8	Secondary osteosarcoma developing 10 years after chemoradiotherapy for non-small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014 , 44, 191-4	2.8	2
7	Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer. <i>Cancer Science</i> , 2013 , 104, 93-7	6.9	28
6	Short hydration in chemotherapy containing cisplatin (75 mg/m ²) for patients with lung cancer: a prospective study. <i>Japanese Journal of Clinical Oncology</i> , 2013 , 43, 1105-9	2.8	36
5	Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor. <i>Cancer Science</i> , 2012 , 103, 756-9	6.9	14
4	Phase I study of concurrent high-dose three-dimensional conformal radiotherapy with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 953-9	4	9
3	Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 177-82	8.9	41
2	Multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 7070-7070	2.2	2
1	Innovator and generic cisplatin formulations: comparison of renal toxicity. <i>Cancer Science</i> , 2011 , 102, 162-5	6.9	24